Using Artificial Intelligence
By Suzie Siegel
1/23/26
If you take information word-for-word from a publication, you should attribute it to the source. The same goes for AI. Put the information in quotation marks and attribute it to ChatGPT, Grok, or whichever AI produced it.
You don’t want to give the impression that you wrote something that you didn’t. You don’t want readers to think you know more than you do.
Depending on what sources they use, AIs may not give answers as comprehensive as knowledgeable humans. For example, someone on X (formerly Twitter) asked Grok if there were any new treatments for LMS. Grok mentioned trabectedin + doxorubicin; catequentinib; and olaparib + temozolomide.
I replied: “Keep in mind that some treatments will not mention leiomyosarcoma specifically but might still apply.”
Grok: “You're right—many treatments for soft tissue sarcomas (STS) can apply to leiomyosarcoma even if not specified. For instance, pazopanib is approved for advanced STS and has been used in LMS cases, as in a 2025 Frontiers case report where it contributed to prolonged survival in multi-line therapy. Check http://clinicaltrials.gov for trials and consult your oncologist.”
Me: “Also, Grok, some treatments for cancers with specific genetic mutations may also benefit LMS patients with the same mutations. Olaparib is an example and might be used ‘off-label.’ “
Grok: “That’s an important addition—olaparib (a PARP inhibitor) has shown promise off-label for LMS with mutations in homologous recombination genes like BRCA2. A 2025 case report detailed four-year recurrence-free survival in a metastatic uterine LMS patient on olaparib. Genetic testing is key; search http://clinicaltrials.gov for related trials and discuss with your oncologist for personalized options.”
Suzie Siegel is a retired newspaper editor and a 23-year survivor of LMS. She lives in Tampa, Florida, with her beloved Chihuahuas. She writes about LMS research @SuzieSiegel on X.com and on her blog at suziesiegel.wordpress.com.